Vertex Pharmaceuticals director proposes $148K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vertex Pharmaceuticals Inc. (VRTX) director Sangeeta N. Bhatia filed a notice of a proposed sale of 271 common shares, with an aggregate market value of $148,470.06 and an approximate sale date of November 16, 2026. The shares were acquired through restricted stock vesting on May 1, 2025; the notice lists August 13, 2026 in the field for the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Vesting financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What date does the VRTX notice list for the Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.